Investigation of the Impact of Smoking Status on Allergen-induced Nasal Airway Inflammation Using a Cat Hair (Felis Domesticus) Extract Nasal Allergen Challenge Model (Kitty Nose)
Primary Purpose
Tobacco Smoking, Healthy Participants, E-cigarette Smokers
Status
Withdrawn
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Felis Domesticus
Sponsored by
About this trial
This is an interventional basic science trial for Tobacco Smoking
Eligibility Criteria
Inclusion Criteria:
- Males and females age 18-50 years
- Specific allergy to cat hair Felis domesticus confirmed by positive immediate skin test response
- Subjects may be enrolled with mild asthma if a Forced Expiratory Volume in 1 second (FEV1) of at least 80% of predicted and a Forced Expiratory Volume in 1 second to Forced Vital Capacity (FVC) ratio (FEV1/FVC ratio) of at least .75 (without use of bronchodilator medications for 12 hours), consistent with lung function of persons with mild episodic or mild persistent asthma is demonstrated. For the purpose of this protocol, an asthmatic individual will be defined as having a) positive methacholine challenge with a provocative concentration of methacholine producing a 20% fall in FEV1 (PC20 methacholine) with less than or equal to 10 mg/ml; OR b) physician diagnosed asthma with symptoms and chronic daily therapy consistent with the mild asthma
- Ability to withhold antihistamine medications for one week prior to baseline and allergen challenge visits.
- Subjects must be able and willing to give informed consent.
- Subjects will be classified as tobacco smokers, e-cigarette users, or non-smokers
Exclusion Criteria:
- Any chronic medical condition considered by the PI as a contraindication to the allergen challenge study including significant cardiovascular disease, diabetes requiring medication, chronic renal disease, bleeding disorder, or chronic thyroid disease.
- Physician directed emergency treatment for an asthma exacerbation within the preceding 12 months.
- Use of systemic steroid therapy within the preceding 12 months for treatment of an asthma exacerbation.
- Use of inhaled or nasal steroids, cromolyn or leukotriene receptor antagonists (Montelukast or Zafirkulast) within the past month (except for use of cromolyn exclusively prior to exercise).
- Use of allergen immunotherapy.
- Use of daily theophylline within the past month.
- Use of nasal medications that might alter the response to nasal allergen challenge including anti-inflammatory and anti-histamine agents within one week of challenge.
- Inability to withhold inhaled or oral bronchodilator medications for 12 hours prior to allergen challenge.
- Pregnancy or nursing a baby.
- Women of child-bearing age who are not using dependable contraception (such as birth control pills, IUD, estrogen patches) or who are not completely abstinent.
- Nighttime symptoms of cough or wheeze greater than 1x/week at baseline (not during a clearly recognized viral induced asthma exacerbation) which would be characteristic of a person of moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma.
- Exacerbation of asthma more than 2x/week which would be characteristic of a person with moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma.
- Daily requirement for albuterol due to asthma symptoms (cough, wheeze, chest tightness) which would be characteristic of a person of moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma. (Not to include prophylactic use of albuterol prior to exercise).
- Viral upper respiratory tract infection within 4 weeks of challenge.
- Any acute infection requiring antibiotics within 4 weeks of challenge.
- Participating in an allergen inhalation study within 2 weeks of this challenge or use of any investigational agent within the last 30 days.
- Use of tricyclic antidepressants or beta-blockers.
- Use of MAO inhibitors or any medications known to interfere with the treatment of anaphylaxis.
- Subjects with a history of immunologic disease or undergoing immune suppression for cancer or other diseases.
- Subjects with acute inflammatory conditions in the nose or paranasal sinuses, such as sinusitis.
Sites / Locations
- UNC Center for Environmental Medicine, Asthma and Lung Biology
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
Felis Domesticus treated Non-smoker
Felis Domesticus treated E-cigarette smoker
Felis Domesticus treated Cigarette smoker
Arm Description
Outcomes
Primary Outcome Measures
Change in eosinophils/mL in nasal lavage fluid (NLF)
NLF will be collected immediately prior to administration of the nasal allergen challenge. 4 hours after administration of a bolus provocative dose of allergen (determined at screening day visit nasal allergen challenge), NLF will be collected. Pre- and 4 hours post-challenge NLF will be analyzed for cellularity. Values will be compared across e-cigarette smokers, tobacco cigarette smokers, and non-smokers.
Secondary Outcome Measures
Nasal lavage fluid cytokines
NLF will be collected immediately prior to administration of the nasal allergen challenge, and 4 hours post-nasal allergen challenge. Cytokine levels will be quantified with commercially available ELISAs.
Nasal epithelial cell messenger ribonucleic acid (mRNA)
Nasal epithelial cell biopsies will be collected at baseline (within two months of nasal allergen challenge), and 4 hours post-nasal allergen challenge. Gene expression changes will be quantified using qRT-PCR.
Full Information
NCT ID
NCT03031145
First Posted
January 21, 2017
Last Updated
May 5, 2021
Sponsor
University of North Carolina, Chapel Hill
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
1. Study Identification
Unique Protocol Identification Number
NCT03031145
Brief Title
Investigation of the Impact of Smoking Status on Allergen-induced Nasal Airway Inflammation Using a Cat Hair (Felis Domesticus) Extract Nasal Allergen Challenge Model
Acronym
Kitty Nose
Official Title
Investigation of the Impact of Smoking Status on Allergen-induced Nasal Airway Inflammation Using a Cat Hair (Felis Domesticus) Extract Nasal Allergen Challenge Model
Study Type
Interventional
2. Study Status
Record Verification Date
May 2021
Overall Recruitment Status
Withdrawn
Why Stopped
Lack of funding
Study Start Date
April 3, 2017 (Actual)
Primary Completion Date
December 4, 2017 (Actual)
Study Completion Date
December 4, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of North Carolina, Chapel Hill
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this pilot study is to evaluate allergen-induced nasal airway inflammation following nasal application of felis domesticus, or cat, extract in e-cigarette users, cigarette smokers, and non-smokers.
Detailed Description
The recent increase in popularity of e-cigarettes for smoking cessation or in combination with conventional cigarettes has let to safety concerns regarding their potential role in respiratory disease. These tobacco alternatives devices were initially perceived as a "safer" alternative to cigarettes and were marketed without much known about their health effects. Increasing evidence that while they contain fewer toxins and carcinogens than conventional cigarettes, they do involve delivery of ultrafine particles to the lower airways and can contain heavy metals and other chemicals. Tobacco Smoke may augment allergic inflammation resulting from allergic rhinitis and/or asthma. Animal models of allergic asthma demonstrate aggravation of allergen -induced airway inflammation following inhalation of e-cig cartridge solution, with increased airway eosinophil infiltration, production of Th2 cytokines, and airway hyperresponsivness. In vitro studies in human tissues have demonstrated pro-inflammatory responses in a similar way as tobacco smoke, yet a head-to-head comparison of the effects of these two exposures has not been performed in humans.
Use of tobacco products remains a pervasive problem in our society and around the world, with significant impact on respiratory health and quality of life. With the emergence of new non-tobacco based nicotine products like e-cigarettes, it is important to understand the impact these substances have on respiratory health and disease. The aim o f this study is to study the impact of these products on allergic inflammation in cat allergic subjects who already routinely use e-cigarettes and to compare their response to those of cigarette smokers and non-smokers. A thorough understanding of the potential health impacts of tobacco alternative substances in seeded, especially given the rising popularity of such products with adolescents and young adults to whom these substances have particular appeals given the purported safety: and variety of flavors to chose from.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tobacco Smoking, Healthy Participants, E-cigarette Smokers
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Felis Domesticus treated Non-smoker
Arm Type
Active Comparator
Arm Title
Felis Domesticus treated E-cigarette smoker
Arm Type
Active Comparator
Arm Title
Felis Domesticus treated Cigarette smoker
Arm Type
Active Comparator
Intervention Type
Biological
Intervention Name(s)
Felis Domesticus
Other Intervention Name(s)
Cat Allergen
Intervention Description
Nasal Administration of Felis Domesticus
Primary Outcome Measure Information:
Title
Change in eosinophils/mL in nasal lavage fluid (NLF)
Description
NLF will be collected immediately prior to administration of the nasal allergen challenge. 4 hours after administration of a bolus provocative dose of allergen (determined at screening day visit nasal allergen challenge), NLF will be collected. Pre- and 4 hours post-challenge NLF will be analyzed for cellularity. Values will be compared across e-cigarette smokers, tobacco cigarette smokers, and non-smokers.
Time Frame
Pre- and 4 hours post- nasal allergen challenge
Secondary Outcome Measure Information:
Title
Nasal lavage fluid cytokines
Description
NLF will be collected immediately prior to administration of the nasal allergen challenge, and 4 hours post-nasal allergen challenge. Cytokine levels will be quantified with commercially available ELISAs.
Time Frame
Pre- and 4 hours post- nasal allergen challenge
Title
Nasal epithelial cell messenger ribonucleic acid (mRNA)
Description
Nasal epithelial cell biopsies will be collected at baseline (within two months of nasal allergen challenge), and 4 hours post-nasal allergen challenge. Gene expression changes will be quantified using qRT-PCR.
Time Frame
Baseline (within two months of nasal allergen challenge) and 4 hours post- nasal allergen challenge
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Males and females age 18-50 years
Specific allergy to cat hair Felis domesticus confirmed by positive immediate skin test response
Subjects may be enrolled with mild asthma if a Forced Expiratory Volume in 1 second (FEV1) of at least 80% of predicted and a Forced Expiratory Volume in 1 second to Forced Vital Capacity (FVC) ratio (FEV1/FVC ratio) of at least .75 (without use of bronchodilator medications for 12 hours), consistent with lung function of persons with mild episodic or mild persistent asthma is demonstrated. For the purpose of this protocol, an asthmatic individual will be defined as having a) positive methacholine challenge with a provocative concentration of methacholine producing a 20% fall in FEV1 (PC20 methacholine) with less than or equal to 10 mg/ml; OR b) physician diagnosed asthma with symptoms and chronic daily therapy consistent with the mild asthma
Ability to withhold antihistamine medications for one week prior to baseline and allergen challenge visits.
Subjects must be able and willing to give informed consent.
Subjects will be classified as tobacco smokers, e-cigarette users, or non-smokers
Exclusion Criteria:
Any chronic medical condition considered by the PI as a contraindication to the allergen challenge study including significant cardiovascular disease, diabetes requiring medication, chronic renal disease, bleeding disorder, or chronic thyroid disease.
Physician directed emergency treatment for an asthma exacerbation within the preceding 12 months.
Use of systemic steroid therapy within the preceding 12 months for treatment of an asthma exacerbation.
Use of inhaled or nasal steroids, cromolyn or leukotriene receptor antagonists (Montelukast or Zafirkulast) within the past month (except for use of cromolyn exclusively prior to exercise).
Use of allergen immunotherapy.
Use of daily theophylline within the past month.
Use of nasal medications that might alter the response to nasal allergen challenge including anti-inflammatory and anti-histamine agents within one week of challenge.
Inability to withhold inhaled or oral bronchodilator medications for 12 hours prior to allergen challenge.
Pregnancy or nursing a baby.
Women of child-bearing age who are not using dependable contraception (such as birth control pills, IUD, estrogen patches) or who are not completely abstinent.
Nighttime symptoms of cough or wheeze greater than 1x/week at baseline (not during a clearly recognized viral induced asthma exacerbation) which would be characteristic of a person of moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma.
Exacerbation of asthma more than 2x/week which would be characteristic of a person with moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma.
Daily requirement for albuterol due to asthma symptoms (cough, wheeze, chest tightness) which would be characteristic of a person of moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma. (Not to include prophylactic use of albuterol prior to exercise).
Viral upper respiratory tract infection within 4 weeks of challenge.
Any acute infection requiring antibiotics within 4 weeks of challenge.
Participating in an allergen inhalation study within 2 weeks of this challenge or use of any investigational agent within the last 30 days.
Use of tricyclic antidepressants or beta-blockers.
Use of MAO inhibitors or any medications known to interfere with the treatment of anaphylaxis.
Subjects with a history of immunologic disease or undergoing immune suppression for cancer or other diseases.
Subjects with acute inflammatory conditions in the nose or paranasal sinuses, such as sinusitis.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michelle Hernandez, MD
Organizational Affiliation
University of North Carolina
Official's Role
Principal Investigator
Facility Information:
Facility Name
UNC Center for Environmental Medicine, Asthma and Lung Biology
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599-7310
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Investigation of the Impact of Smoking Status on Allergen-induced Nasal Airway Inflammation Using a Cat Hair (Felis Domesticus) Extract Nasal Allergen Challenge Model
We'll reach out to this number within 24 hrs